204 related articles for article (PubMed ID: 29261796)
21. High-dose interleukin-2 therapy for metastatic renal cell carcinoma: a contemporary experience.
Hanzly M; Aboumohamed A; Yarlagadda N; Creighton T; Digiorgio L; Fredrick A; Rao G; Mehedint D; George S; Attwood K; Kauffman E; Narashima D; Khushalani NI; Pili R; Schwaab T
Urology; 2014 May; 83(5):1129-34. PubMed ID: 24767525
[TBL] [Abstract][Full Text] [Related]
22. High-dose interleukin-2 (HD IL-2) for advanced melanoma: a single center experience from the University of Pittsburgh Cancer Institute.
Davar D; Ding F; Saul M; Sander C; Tarhini AA; Kirkwood JM; Tawbi HA
J Immunother Cancer; 2017 Sep; 5(1):74. PubMed ID: 28923120
[TBL] [Abstract][Full Text] [Related]
23. The high-dose aldesleukin "select" trial: a trial to prospectively validate predictive models of response to treatment in patients with metastatic renal cell carcinoma.
McDermott DF; Cheng SC; Signoretti S; Margolin KA; Clark JI; Sosman JA; Dutcher JP; Logan TF; Curti BD; Ernstoff MS; Appleman L; Wong MK; Khushalani NI; Oleksowicz L; Vaishampayan UN; Mier JW; Panka DJ; Bhatt RS; Bailey AS; Leibovich BC; Kwon ED; Kabbinavar FF; Belldegrun AS; Figlin RA; Pantuck AJ; Regan MM; Atkins MB
Clin Cancer Res; 2015 Feb; 21(3):561-8. PubMed ID: 25424850
[TBL] [Abstract][Full Text] [Related]
24. Prognostic significance of sarcomatoid features in metastatic renal cell carcinoma treated with cytoreductive nephrectomy and targeted therapy.
Cortese BD; Chelluri R; Xia L; Ostrowski DA; Roberson DS; Strother M; Ding JM; Schwartz L; Lee DJ; Guzzo TJ
Am J Clin Exp Urol; 2022; 10(5):327-333. PubMed ID: 36313210
[TBL] [Abstract][Full Text] [Related]
25. Sarcomatoid dedifferentiation in metastatic clear cell renal cell carcinoma and outcome on treatment with anti-vascular endothelial growth factor receptor tyrosine kinase inhibitors: a retrospective analysis.
Beuselinck B; Lerut E; Wolter P; Dumez H; Berkers J; Van Poppel H; Joniau S; Oyen R; De Wever L; Strijbos M; Paridaens R; Schöffski P
Clin Genitourin Cancer; 2014 Oct; 12(5):e205-14. PubMed ID: 24861951
[TBL] [Abstract][Full Text] [Related]
26. Impact of histologic subtype and sarcomatoid transformation on metastasis in renal cell carcinoma: a single institute experience in 149 patients.
Tirumani SH; Souza D; Krajewski KM; Jagannathan JP; Ramaiya NH; Shinagare AB
Abdom Radiol (NY); 2016 Feb; 41(2):295-302. PubMed ID: 26867911
[TBL] [Abstract][Full Text] [Related]
27. Contemporary experience with high-dose interleukin-2 therapy and impact on survival in patients with metastatic melanoma and metastatic renal cell carcinoma.
Alva A; Daniels GA; Wong MK; Kaufman HL; Morse MA; McDermott DF; Clark JI; Agarwala SS; Miletello G; Logan TF; Hauke RJ; Curti B; Kirkwood JM; Gonzalez R; Amin A; Fishman M; Agarwal N; Lowder JN; Hua H; Aung S; Dutcher JP
Cancer Immunol Immunother; 2016 Dec; 65(12):1533-1544. PubMed ID: 27714434
[TBL] [Abstract][Full Text] [Related]
28. Tumour burden is an independent prognostic factor in metastatic renal cell carcinoma.
Iacovelli R; Lanoy E; Albiges L; Escudier B
BJU Int; 2012 Dec; 110(11):1747-53. PubMed ID: 23106948
[TBL] [Abstract][Full Text] [Related]
29. The independent oncological role for cytoreductive nephrectomy in metastatic renal cell carcinoma: Prognostic features in the era of targeted therapies.
Claeys T; Lumen N; Kumps C; Praet M; De Meerleer G; Rottey S; Ost P; Devisschere P; Villeirs G; Fonteyne V; Decaestecker K
Urol Oncol; 2017 Apr; 35(4):152.e13-152.e22. PubMed ID: 28153420
[TBL] [Abstract][Full Text] [Related]
30. Long-term follow-up of patients with metastatic renal cell carcinoma treated with intravenous recombinant interleukin-2 in Europe.
Negrier S; Maral J; Drevon M; Vinke J; Escudier B; Philip T
Cancer J Sci Am; 2000 Feb; 6 Suppl 1():S93-8. PubMed ID: 10685667
[TBL] [Abstract][Full Text] [Related]
31. Outcomes of patients with metastatic renal cell carcinoma with sarcomatoid dedifferentiation to immune checkpoint inhibitors.
Chahoud J; Msaouel P; Ross JA; McCormick BZ; Bathala TK; Gao J; Horn R; Xiao L; Sircar K; Campbell MT; Shah AY; Goswami S; Zurita AJ; Jonasch E; Matin SF; Wood CG; Karam JA; Sharma P; Tannir NM
Urol Oncol; 2021 Feb; 39(2):134.e9-134.e16. PubMed ID: 33187886
[TBL] [Abstract][Full Text] [Related]
32. First experience of active surveillance before systemic target therapy in patients with metastatic renal cell carcinoma.
Matsubara N; Mukai H; Naito Y; Itoh K; Komai Y; Sakai Y
Urology; 2013 Jul; 82(1):118-23. PubMed ID: 23806397
[TBL] [Abstract][Full Text] [Related]
33. Prognostic factors for survival in patients with metastatic renal cancer treated with biological response modifiers.
Mani S; Todd MB; Katz K; Poo WJ
J Urol; 1995 Jul; 154(1):35-40. PubMed ID: 7539867
[TBL] [Abstract][Full Text] [Related]
34. Progression free survival of first line vascular endothelial growth factor-targeted therapy is an important prognostic parameter in patients with metastatic renal cell carcinoma.
Seidel C; Busch J; Weikert S; Steffens S; Fenner M; Ganser A; Grünwald V
Eur J Cancer; 2012 May; 48(7):1023-30. PubMed ID: 22436979
[TBL] [Abstract][Full Text] [Related]
35. A Korean multi-center, real-world, retrospective study of first-line pazopanib in unselected patients with metastatic renal clear-cell carcinoma.
Kim MJ; Park SH; Lee JL; Lee SH; Lee SJ; Lim HY
BMC Urol; 2016 Aug; 16(1):46. PubMed ID: 27484998
[TBL] [Abstract][Full Text] [Related]
36. Cytoreductive nephrectomy for metastatic renal cell carcinoma with nonclear cell histology.
Kassouf W; Sanchez-Ortiz R; Tamboli P; Tannir N; Jonasch E; Merchant MM; Matin S; Swanson DA; Wood CG
J Urol; 2007 Nov; 178(5):1896-900. PubMed ID: 17868729
[TBL] [Abstract][Full Text] [Related]
37. Phase II study of pazopanib as second-line treatment after sunitinib in patients with metastatic renal cell carcinoma: a Southern China Urology Cancer Consortium Trial.
Xie M; He CS; Huang JK; Lin QZ
Eur J Cancer; 2015 Mar; 51(5):595-603. PubMed ID: 25618828
[TBL] [Abstract][Full Text] [Related]
38. Impact of Sequencing Targeted Therapies With High-dose Interleukin-2 Immunotherapy: An Analysis of Outcome and Survival of Patients With Metastatic Renal Cell Carcinoma From an On-going Observational IL-2 Clinical Trial: PROCLAIM
Clark JI; Wong MKK; Kaufman HL; Daniels GA; Morse MA; McDermott DF; Agarwala SS; Lewis LD; Stewart JH; Vaishampayan U; Curti B; Gonzalez R; Lutzky J; Rudraptna V; Cranmer LD; Jeter JM; Hauke RJ; Miletello G; Milhem MM; Amin A; Richart JM; Fishman M; Hallmeyer S; Patel SP; Van Veldhuizen P; Agarwal N; Taback B; Treisman JS; Ernstoff MS; Perritt JC; Hua H; Rao TB; Dutcher JP; Aung S
Clin Genitourin Cancer; 2017 Feb; 15(1):31-41.e4. PubMed ID: 27916626
[TBL] [Abstract][Full Text] [Related]
39. Treatment Outcome of Low-dose Interleukin-2 Therapy in Patients with Metastatic Renal Cell Carcinoma.
Takezawa Y; Izumi K; Shimura Y; Aerken M; Natsagdorji A; Iijima M; Shigehara K; Nohara T; Narimoto K; Kadono Y; Kitagawa Y; Konaka H; Mizokami A
Anticancer Res; 2016 Sep; 36(9):4961-4. PubMed ID: 27630356
[TBL] [Abstract][Full Text] [Related]
40. Real world prospective experience of axitinib in metastatic renal cell carcinoma in a large comprehensive cancer centre.
Matias M; Le Teuff G; Albiges L; Guida A; Brard C; Bacciarelo G; Loriot Y; Massard C; Lassau N; Fizazi K; Escudier B
Eur J Cancer; 2017 Jul; 79():185-192. PubMed ID: 28511146
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]